Tag: BioTech

Shares in psychedelic-derived therapeutics company, Clearmind Medicine (Nasdaq: CMND), surged on Monday after the company announced it will participate in the 2024 Psychedelic Medicine –… [Read More]

CytoSorbents Corporation (Nasdaq: CTSO) has secured regulatory approval from the Taiwan Food and Drug Administration (TFDA) for CytoSorb®, the company’s extracorporeal cytokine adsorber that reduces… [Read More]

Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is building sustainable value for investors and setting itself apart through its strategic targeting of attractive addressable patient… [Read More]

Shares in the women’s healthcare company, Agile Therapeutics (OTC: AGRX), surged by more than 320% in morning trading on Wednesday after the company announced it… [Read More]

Antimicrobial resistance (AMR) is currently one of the greatest threats to public health globally. Eli Lilly (NYSE: LLY)has announced that it will collaborate with the… [Read More]

Late-stage biopharmaceutical company, Soligenix, Inc (Nasdaq: SNGX), has announced positive clinical results from a 12-week study of its lead product candidate, HyBryte™ (synthetic hypericin), which… [Read More]

This month, precision diagnostics company, Oncocyte Corporation (Nasdaq: OCX) further strengthened its leadership team with the appointment of leading finance executive Andrea James as Chief… [Read More]

Alto Neuroscience (NYSE: ANRO) has initiated a Phase 2 double-blind, placebo-controlled study of a transdermal formulation of ALTO-101 for the treatment of cognitive impairment associated… [Read More]

Immunotherapy company, Enlivex Therapeutics (Nasdaq: ENLV), has released positive data from its Phase 1/2 investigator-initiated clinical trial of AllocetraTM in patients with end-stage knee osteoarthritis…. [Read More]

MIRA Pharmaceuticals (Nasdaq: MIRA) is advancing closer to clinical development of what could potentially be the first at-home ketamine-based treatment for post-traumatic stress disorder (PTSD)…. [Read More]

Pharmaceutical company, Moleculin Biotech (Nasdaq: MBRX), has initiated an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of glioblastoma…. [Read More]